Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Cardiovascular effects of pioglitazone or sulphonylureas according to pretreatment risk: moving towards personalized care.

Vaccaro O, Lucisano G, Masulli M, Bonora E, Del Prato S, Rivellese AA, Giorda CB, Mocarelli P, Squatrito S, Maggioni AP, Riccardi G, Nicolucci A; TOSCA.IT investigators.

J Clin Endocrinol Metab. 2019 May 6. pii: jc.2019-00361. doi: 10.1210/jc.2019-00361. [Epub ahead of print]

PMID:
31058962
2.

Long-term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study.

Sartore G, Chilelli NC, Seraglia R, Ragazzi E, Marin R, Roverso M, Cosma C, Vaccaro O, Burlina S, Lapolla A.

Acta Diabetol. 2019 May;56(5):505-513. doi: 10.1007/s00592-018-01278-2. Epub 2019 Feb 10.

PMID:
30740640
3.

Impact of a Mediterranean Dietary Pattern and Its Components on Cardiovascular Risk Factors, Glucose Control, and Body Weight in People with Type 2 Diabetes: A Real-Life Study.

Vitale M, Masulli M, Calabrese I, Rivellese AA, Bonora E, Signorini S, Perriello G, Squatrito S, Buzzetti R, Sartore G, Babini AC, Gregori G, Giordano C, Clemente G, Grioni S, Dolce P, Riccardi G, Vaccaro O; TOSCA.IT Study Group.

Nutrients. 2018 Aug 10;10(8). pii: E1067. doi: 10.3390/nu10081067.

4.

Risk of heart failure in diabetic patients receiving sulfonylureas.

Vaccaro O, Riccardi G, Maggioni AP.

Eur J Heart Fail. 2018 Sep;20(9):1371-1372. doi: 10.1002/ejhf.1238. Epub 2018 Jun 22. No abstract available.

PMID:
29932487
5.

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.

Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):887-897. doi: 10.1016/S2213-8587(17)30317-0. Epub 2017 Sep 13. Erratum in: Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7.

PMID:
28917544
6.

Polyphenol intake and cardiovascular risk factors in a population with type 2 diabetes: The TOSCA.IT study.

Vitale M, Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Nicolucci A, Squatrito S, Auciello S, Babini AC, Bani L, Buzzetti R, Cannarsa E, Cignarelli M, Cigolini M, Clemente G, Cocozza S, Corsi L, D'Angelo F, Dall'Aglio E, Di Cianni G, Fontana L, Gregori G, Grioni S, Giordano C, Iannarelli R, Iovine C, Lapolla A, Lauro D, Laviola L, Mazzucchelli C, Signorini S, Tonutti L, Trevisan R, Zamboni C, Riccardi G, Rivellese AA; TOSCA.IT Study Group.

Clin Nutr. 2017 Dec;36(6):1686-1692. doi: 10.1016/j.clnu.2016.11.002. Epub 2016 Nov 14.

PMID:
27890487
7.

How Well Can We Control Dyslipidemias Through Lifestyle Modifications?

Riccardi G, Vaccaro O, Costabile G, Rivellese AA.

Curr Cardiol Rep. 2016 Jul;18(7):66. doi: 10.1007/s11886-016-0744-7. Review.

PMID:
27216846
8.

A 19 year follow-up of a woman with lipoprotein lipase deficiency treated with biliopancreatic diversion.

Nosso G, Capaldo B, Cocozza S, Vaccaro O.

Clin Case Rep. 2015 Nov 5;3(12):1030-3. doi: 10.1002/ccr3.433. eCollection 2015 Dec.

9.

The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes.

Lapice E, Monticelli A, Cocozza S, Pinelli M, Cocozza S, Bruzzese D, Riccardi G, Vaccaro O.

J Transl Med. 2015 Mar 12;13:85. doi: 10.1186/s12967-015-0448-6.

10.

Interaction between Pro12Ala polymorphism of PPARγ2 and diet on adiposity phenotypes.

Lapice E, Vaccaro O.

Curr Atheroscler Rep. 2014 Dec;16(12):462. doi: 10.1007/s11883-014-0462-9. Review.

PMID:
25342491
11.

Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes.

Vaccaro O, Masulli M, Bonora E, Del Prato S, Riccardi G; TOSCA.IT Study Group.

Lancet. 2014 Sep 20;384(9948):1096. doi: 10.1016/S0140-6736(14)61672-X. No abstract available.

PMID:
25241718
12.

Obesity attenuates gender differences in cardiovascular mortality.

Song X, Tabák AG, Zethelius B, Yudkin JS, Söderberg S, Laatikainen T, Stehouwer CD, Dankner R, Jousilahti P, Onat A, Nilsson PM, Satman I, Vaccaro O, Tuomilehto J, Qiao Q; DECODE Study Group.

Cardiovasc Diabetol. 2014 Oct 19;13:144. doi: 10.1186/s12933-014-0144-5.

13.

Iron deficiency and cardiovascular disease: an updated review of the evidence.

Lapice E, Masulli M, Vaccaro O.

Curr Atheroscler Rep. 2013 Oct;15(10):358. doi: 10.1007/s11883-013-0358-0. Review.

PMID:
24057693
14.

Hypertensive target organ damage predicts incident diabetes mellitus.

Izzo R, de Simone G, Trimarco V, Gerdts E, Giudice R, Vaccaro O, De Luca N, Trimarco B.

Eur Heart J. 2013 Nov;34(44):3419-26. doi: 10.1093/eurheartj/eht281. Epub 2013 Jul 23.

15.

Feasibility and effectiveness in clinical practice of a multifactorial intervention for the reduction of cardiovascular risk in patients with type 2 diabetes: the 2-year interim analysis of the MIND.IT study: a cluster randomized trial.

Vaccaro O, Franzini L, Miccoli R, Cavalot F, Ardigò D, Boemi M, De Feo P, Reboldi G, Rivellese AA, Trovati M, Zavaroni I; MIND.IT Study Group.

Diabetes Care. 2013 Sep;36(9):2566-72. doi: 10.2337/dc12-1781. Epub 2013 Jul 17.

16.

Renal duplex sonographic evaluation of type 2 diabetic patients.

Mancini M, Masulli M, Liuzzi R, Mainenti PP, Ragucci M, Maurea S, Riccardi G, Vaccaro O.

J Ultrasound Med. 2013 Jun;32(6):1033-40. doi: 10.7863/ultra.32.6.1033.

PMID:
23716525
18.

The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes.

Vaccaro O, Masulli M, Bonora E, Del Prato S, Nicolucci A, Rivellese AA, Riccardi G; TOSCA.IT Study Group.

Diabetes Care. 2012 Dec;35(12):e82. doi: 10.2337/dc12-0954. No abstract available.

19.

Effectiveness of treat-to-target strategy for LDL-cholesterol control in type 2 diabetes: post-hoc analysis of data from the MIND.IT study.

Ardigò D, Vaccaro O, Cavalot F, Rivellese AA, Franzini L, Miccoli R, Patti L, Boemi M, Trovati M, Zavaroni I; MIND.IT study group.

Eur J Prev Cardiol. 2014 Apr;21(4):456-63. doi: 10.1177/2047487312467746. Epub 2012 Nov 12.

PMID:
23147277
20.

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.

Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivellese AA, Squatrito S, Riccardi G; TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial).

Nutr Metab Cardiovasc Dis. 2012 Nov;22(11):997-1006. doi: 10.1016/j.numecd.2012.09.003. Epub 2012 Oct 11.

PMID:
23063367

Supplemental Content

Loading ...
Support Center